BRPI0816221A8 - forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida - Google Patents

forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Info

Publication number
BRPI0816221A8
BRPI0816221A8 BRPI0816221A BRPI0816221A BRPI0816221A8 BR PI0816221 A8 BRPI0816221 A8 BR PI0816221A8 BR PI0816221 A BRPI0816221 A BR PI0816221A BR PI0816221 A BRPI0816221 A BR PI0816221A BR PI0816221 A8 BRPI0816221 A8 BR PI0816221A8
Authority
BR
Brazil
Prior art keywords
methylpyrrolidin
benzimidazol
carboxamide
crystalline form
crystalline
Prior art date
Application number
BRPI0816221A
Other languages
English (en)
Portuguese (pt)
Inventor
Lawrence Kolaczkowski
Original Assignee
Abbott Lab
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0816221(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Abbvie Inc filed Critical Abbott Lab
Publication of BRPI0816221A2 publication Critical patent/BRPI0816221A2/pt
Publication of BRPI0816221A8 publication Critical patent/BRPI0816221A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0816221A 2007-10-12 2008-10-10 forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida BRPI0816221A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12
PCT/US2008/079441 WO2009049111A1 (en) 2007-10-12 2008-10-10 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Publications (2)

Publication Number Publication Date
BRPI0816221A2 BRPI0816221A2 (pt) 2015-06-16
BRPI0816221A8 true BRPI0816221A8 (pt) 2015-09-22

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816221A BRPI0816221A8 (pt) 2007-10-12 2008-10-10 forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Country Status (27)

Country Link
US (4) US8372987B2 (ja)
EP (2) EP2722046B1 (ja)
JP (4) JP2011500589A (ja)
KR (2) KR20160039312A (ja)
CN (2) CN101821270A (ja)
AU (1) AU2008310781B2 (ja)
BR (1) BRPI0816221A8 (ja)
CA (2) CA2696424C (ja)
CO (1) CO6280493A2 (ja)
CR (1) CR11368A (ja)
DK (1) DK2722046T3 (ja)
DO (1) DOP2010000099A (ja)
EC (1) ECSP10010150A (ja)
ES (1) ES2620299T3 (ja)
GT (1) GT201000080A (ja)
MX (1) MX350019B (ja)
MY (1) MY156691A (ja)
NZ (1) NZ583209A (ja)
PA (1) PA8798401A1 (ja)
PL (1) PL2722046T3 (ja)
PT (1) PT2722046T (ja)
RU (2) RU2476434C2 (ja)
SG (1) SG185297A1 (ja)
TW (1) TWI422588B (ja)
UA (2) UA113277C2 (ja)
WO (1) WO2009049111A1 (ja)
ZA (1) ZA201002090B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727921B1 (en) 2007-10-12 2017-04-19 AbbVie Ireland Unlimited Company 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 2
ES2620299T3 (es) 2007-10-12 2017-06-28 Abbvie Ireland Unlimited Company Forma cristalina 1 de 2-((R)-2-metilpirrolidin-2-il)-1H-bencimidazol-4-carboxamida
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
CN109071499A (zh) * 2016-03-09 2018-12-21 苏州晶云药物科技股份有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020071931A (ko) * 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP2727921B1 (en) * 2007-10-12 2017-04-19 AbbVie Ireland Unlimited Company 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 2
ES2620299T3 (es) 2007-10-12 2017-06-28 Abbvie Ireland Unlimited Company Forma cristalina 1 de 2-((R)-2-metilpirrolidin-2-il)-1H-bencimidazol-4-carboxamida

Also Published As

Publication number Publication date
KR20100090769A (ko) 2010-08-17
CR11368A (es) 2010-10-25
EP2212327A1 (en) 2010-08-04
WO2009049111A1 (en) 2009-04-16
US20140024838A1 (en) 2014-01-23
US20150148392A1 (en) 2015-05-28
ZA201002090B (en) 2011-11-30
MY156691A (en) 2016-03-15
DOP2010000099A (es) 2017-04-30
KR20160039312A (ko) 2016-04-08
UA101961C2 (en) 2013-05-27
CA2696424A1 (en) 2009-04-16
PA8798401A1 (es) 2009-05-15
RU2476434C2 (ru) 2013-02-27
SG185297A1 (en) 2012-11-29
MX2010003772A (es) 2010-04-21
CA3006332A1 (en) 2009-04-16
BRPI0816221A2 (pt) 2015-06-16
JP2019001811A (ja) 2019-01-10
JP2011500589A (ja) 2011-01-06
TW200932747A (en) 2009-08-01
RU2012147692A (ru) 2014-05-20
CN101821270A (zh) 2010-09-01
DK2722046T3 (en) 2017-03-20
US8372987B2 (en) 2013-02-12
GT201000080A (es) 2012-04-03
US9580410B2 (en) 2017-02-28
JP2014237659A (ja) 2014-12-18
UA113277C2 (xx) 2017-01-10
US8835647B2 (en) 2014-09-16
CO6280493A2 (es) 2011-05-20
US20090099245A1 (en) 2009-04-16
ES2620299T3 (es) 2017-06-28
ECSP10010150A (es) 2010-06-29
AU2008310781B2 (en) 2013-03-28
CA2696424C (en) 2018-07-10
TWI422588B (zh) 2014-01-11
NZ583209A (en) 2012-06-29
PT2722046T (pt) 2017-03-15
RU2010116397A (ru) 2011-11-20
MX350019B (es) 2016-12-09
EP2722046B1 (en) 2016-12-21
US20130123317A1 (en) 2013-05-16
EP2722046A1 (en) 2014-04-23
JP2017071618A (ja) 2017-04-13
AU2008310781A1 (en) 2009-04-16
CN105367554A (zh) 2016-03-02
PL2722046T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
BRPI0922904A2 (pt) "compostos"
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
BRPI0915714A2 (pt) forma cristalina de posaconazol
BRPI0813500A2 (pt) Compostos antivirais
BRPI0821086A2 (pt) Compostos inseticidas
BRPI1012004A2 (pt) "forma farmacêutica"
BRPI0913806A2 (pt) "composição"
BRPI0817169A2 (pt) "artigos"
BRPI0811264A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
FI20075851A0 (fi) Muodostusosa
BRPI0924746A2 (pt) "elemento delizante"
DK2190837T3 (da) 4-pyrimidinsulfamid-derivat
BRPI0809996A2 (pt) Compostos
BRPI0816221A8 (pt) forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
BRPI0815181A2 (pt) Compostos
ATE546446T1 (de) 5-aminocyclylmethyl-oxazolidin-2-eins-derivativ
DK2185151T3 (da) Antiinflammatorisk sammensætning
DK1977652T3 (da) Konfekturesammensætning
BRPI0814613A2 (pt) Compostos
BRPI0819546A2 (pt) "capacitor"
MA30860B1 (fr) Myrtillier denomme "c97-390"
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
ITMI20042437A1 (it) Forma cristallina di rabeprazolo sodico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B25A Requested transfer of rights approved

Owner name: ABBVIE BAHAMAS LTD. (US)

B25A Requested transfer of rights approved

Owner name: ABBVIE IRELAND UNLIMITED COMPANY (BM)

B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 11A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2535 DE 06-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.